Tags

Type your tag names separated by a space and hit enter

Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
Br J Ophthalmol. 2006 Nov; 90(11):1370-3.BJ

Abstract

AIM

To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension.

METHODS

Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months.

RESULTS

No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p> or =0.741). After 6 months, both drugs significantly reduced IOP at every time point (p< or =0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mm Hg (27.9%) with bimatoprost (n = 76) and 5.7 mm Hg (23.3%) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3%) and 5.2 mm Hg (22.4%) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mm Hg (22.5%) with bimatoprost and 4.5 mm Hg (18.9%; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups.

CONCLUSIONS

Bimatoprost provided greater mean IOP reductions than travoprost.

Authors+Show Affiliations

Department of Ophthalmology, Indiana University Medical Center, 702 Rotary Circle, Indianapolis, IN 46202, USA. lcantor@iupui.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16825272

Citation

Cantor, L B., et al. "Intraocular Pressure-lowering Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients With Glaucoma or Ocular Hypertension." The British Journal of Ophthalmology, vol. 90, no. 11, 2006, pp. 1370-3.
Cantor LB, Hoop J, Morgan L, et al. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006;90(11):1370-3.
Cantor, L. B., Hoop, J., Morgan, L., Wudunn, D., & Catoira, Y. (2006). Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. The British Journal of Ophthalmology, 90(11), 1370-3.
Cantor LB, et al. Intraocular Pressure-lowering Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients With Glaucoma or Ocular Hypertension. Br J Ophthalmol. 2006;90(11):1370-3. PubMed PMID: 16825272.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. AU - Cantor,L B, AU - Hoop,J, AU - Morgan,L, AU - Wudunn,D, AU - Catoira,Y, AU - ,, Y1 - 2006/07/06/ PY - 2006/7/11/pubmed PY - 2006/12/12/medline PY - 2006/7/11/entrez SP - 1370 EP - 3 JF - The British journal of ophthalmology JO - Br J Ophthalmol VL - 90 IS - 11 N2 - AIM: To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension. METHODS: Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months. RESULTS: No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p> or =0.741). After 6 months, both drugs significantly reduced IOP at every time point (p< or =0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mm Hg (27.9%) with bimatoprost (n = 76) and 5.7 mm Hg (23.3%) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3%) and 5.2 mm Hg (22.4%) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mm Hg (22.5%) with bimatoprost and 4.5 mm Hg (18.9%; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups. CONCLUSIONS: Bimatoprost provided greater mean IOP reductions than travoprost. SN - 0007-1161 UR - https://www.unboundmedicine.com/medline/citation/16825272/Intraocular_pressure_lowering_efficacy_of_bimatoprost_0_03_and_travoprost_0_004_in_patients_with_glaucoma_or_ocular_hypertension_ L2 - http://bjo.bmj.com/cgi/pmidlookup?view=long&amp;pmid=16825272 DB - PRIME DP - Unbound Medicine ER -